RxDoctor Payments Data

Aaron Ford, MD

Cardiovascular Disease · Hilton Head Island, SCNPI 1740361302

Payments from drug & device makers

$4,308in general payments, 2019–2025

Across 189 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$854
  • Johnson & Johnson$559
  • Novartis$540
  • Boehringer Ingelheim$320
  • Medtronic$301
  • E.r. Squibb & Sons, L.L.C.$194
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,308 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$789,763
Medicare patients
2,000
Services billed
8,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban829$1,030,511
XareltoRivaroxaban236$312,769
EntrestoSacubitril/Valsartan167$228,096
MultaqDronedarone Hcl52$105,203
Repatha SureclickEvolocumab72$73,902
FarxigaDapagliflozin Propanediol43$47,620
JardianceEmpagliflozin32$35,167
NexletolBempedoic Acid44$33,735
Praluent PenAlirocumab23$32,341
WegovySemaglutide22$29,383
Metoprolol Succinate824$12,647
Dabigatran EtexilateDabigatran Etexilate Mesylate23$10,571
Rosuvastatin Calcium488$7,232
Ranolazine ErRanolazine71$6,377
Nebivolol Hcl92$6,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$176$1,030,511829 claims
Johnson & JohnsonXarelto$559$312,769236 claims
NovartisEntresto$540$228,096167 claims
Boehringer IngelheimJardiance$320$35,16732 claims
Novo NordiskWegovy$17$29,38322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Hilton Head Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →